GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:
Jefferies London Virtual Healthcare Conference
Tuesday, November 17, 2020
11:25 am Eastern Time
Piper Sandler 32
nd
Annual Virtual Healthcare Conference
Monday, November 23, 2020 to Thursday, December 3, 2020
Fireside chat recording available to conference participants
3
rd
Annual Evercore ISI
Virtual
HealthCONx Conference
Wednesday, December 2, 2020
8:00 am Eastern Time
The sessions will be webcast and can be accessed by visiting the investor relations section of the company’s website at www.altimmune.com under Events / Presentations.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.
Investor
Contact
s
:
| Stacey Jurchison Altimmune, Investor Relations Phone: 410-474-8200 [email protected] |
Ashley R. Robinson LifeSci Advisors, LLC 617-430-7577 [email protected] |